Despite no direct association of the MFN2 gene with AD, disease-related mutation (R95Q) in MFN2 disrupted mitochondrial transport and fusion, leading to the development of characteristic features of axonal dystrophy (AxD), a key therapeutic target marked by neuritic swellings that contribute to neurotoxic Aβ accumulation and memory loss with little to no detrimental effect on the cell body (Leuner et al., 2012; Silva et al., 2012; Zhou et al., 2021; Misko et al., 2012). The gene discussed is MFN2; the disease is Alzheimer disease.